← Mechanisms of action
PCSK9
SINGLE PROTEINHomo sapiens
Preferred name: Subtilisin/kexin type 9 ChEMBL ↗
Linked proteins
Drugs acting on this target (40)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| azd0780 | Antagonist | experimental | Small molecule | PCSK9 |
| mk-0616 | Antagonist | experimental | Small molecule | PCSK9 antagonist |
| aln-pcs02 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| aro-dimerpa | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| azd8233 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| bms-844421 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| civi007 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| cor-1004 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| cvi-lm001 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| dnv001 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| inclisiran (Leqvio) | Antisense inhibitor | approved | Small molecule | PCSK9 antisense inhibitor |
| rbd7022 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| sgb-3403 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| spc5001 | Antisense inhibitor | experimental | Nucleic acid | PCSK9 antisense inhibitor |
| vxx-401 | Immunity, active | experimental | Vaccine | PCSK9 immunity, active |
| ak102 | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| alirocumab (praluent) | Inhibitor | approved | mAb | PCSK9 inhibitor |
| azd6615 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| bms-962476 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| bococizumab | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| civi 007 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| evolocumab (repatha) | Inhibitor | approved | mAb | PCSK9 inhibitor |
| hs-10510 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| lerodalcibep (Lerochol) | Inhibitor | approved | Recombinant protein | Subtilisin/kexin type 9 inhibitor |
| lgt209 | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| ly3015014 | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| nnc0385-0434 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| Ongericimab | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| pf-06815345 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| ps13 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| qlc7401 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| rg-7652 | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| rn0191 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| shr-1209 | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| syh2053 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| Tafolecimab (SINTBILO) | Inhibitor | experimental | mAb | PCSK9 inhibitor |
| verve-101 | Inhibitor | experimental | Gene therapy | PCSK9 inhibitor |
| verve-102 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| yolt-101 | Inhibitor | experimental | Small molecule | PCSK9 inhibitor |
| art002g1 | Supplementation | experimental | Gene therapy | PCSK9 supplementation |